Lexicon Pharmaceuticals (LXRX) Projected to Post Quarterly Earnings on Thursday

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $1.26 million for the quarter.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last posted its quarterly earnings data on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The firm had revenue of $26.55 million for the quarter, compared to analysts' expectations of $6.48 million. On average, analysts expect Lexicon Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Lexicon Pharmaceuticals Price Performance

Shares of LXRX traded down $0.02 during trading hours on Tuesday, reaching $0.67. 1,557,788 shares of the stock traded hands, compared to its average volume of 6,465,588. Lexicon Pharmaceuticals has a 52-week low of $0.28 and a 52-week high of $2.45. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56. The company has a market cap of $165.23 million, a P/E ratio of -0.90 and a beta of 1.02. The company's 50-day moving average price is $0.49 and its two-hundred day moving average price is $0.82.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Leerink Partnrs cut shares of Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. StockNews.com started coverage on Lexicon Pharmaceuticals in a research report on Monday, April 21st. They set a "sell" rating for the company. HC Wainwright reaffirmed a "buy" rating and set a $4.00 price target on shares of Lexicon Pharmaceuticals in a research note on Friday, March 28th. Piper Sandler reduced their target price on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating on the stock in a report on Friday, March 7th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Lexicon Pharmaceuticals in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $3.67.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

An institutional investor recently raised its position in Lexicon Pharmaceuticals stock. Bank of America Corp DE grew its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 27.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 136,407 shares of the biopharmaceutical company's stock after purchasing an additional 29,319 shares during the period. Bank of America Corp DE owned about 0.06% of Lexicon Pharmaceuticals worth $101,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 74.70% of the company's stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.